Movatterモバイル変換


[0]ホーム

URL:


US3760806A - Helical osmotic dispenser with non-planar membrane - Google Patents

Helical osmotic dispenser with non-planar membrane
Download PDF

Info

Publication number
US3760806A
US3760806AUS00106132AUS3760806DAUS3760806AUS 3760806 AUS3760806 AUS 3760806AUS 00106132 AUS00106132 AUS 00106132AUS 3760806D AUS3760806D AUS 3760806DAUS 3760806 AUS3760806 AUS 3760806A
Authority
US
United States
Prior art keywords
compartment
dispenser
osmotic
active agent
perforated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00106132A
Inventor
H Leeper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza CorpfiledCriticalAlza Corp
Application grantedgrantedCritical
Publication of US3760806ApublicationCriticalpatent/US3760806A/en
Anticipated expirationlegal-statusCritical
Expired - Lifetimelegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

An osmotic active agent dispenser is comprised of: (1) a first helical compartment of relatively impervious material containing an active agent and provided with a dispensing head for releasing active agent to the exterior of the dispenser; (2) a second helical compartment of controlled permeability to water containing a solution of an osmotically effective solute which exhibits an osmotic pressure gradient against water, the second compartment being interconnected with said first compartment to define a continuous helix therewith; and (3) a movable barrier member separating the first from the second compartment. The barrier member is slidably responsive to an increase in volume in the second compartment via absorption of water by osmosis therein; whereby as water flows into the compartment (2) of the dispenser in a tendency towards osmotic equilibrium with its environment, corresponding pressure is exerted behind the barrier (3) driving it into and diminishing the volume of the compartment (1), in turn continuously ejecting active agent thereout at an osmotically controlled rate over a prolonged period of time.

Description

Leeper I-IELICAL OSMOTIC DISPENSER WITH NON-PLANAR MEMBRANE [75] Inventor: Harold M. Leeper, Lawrence, Kans. g [73] Assignee: Alza Corporation, Palo Alto,
Calif.
[22] Filed: Jan. 13, 1971 [21] Appl. No.: 106,132
[52] US. Cl. 128/260, 128/130, 222/386 [51] Int. Cl. A61m 31/00, A61f 5/46 [58] Field of Search 128/260, 127-131, 128/172, 213, 261, 272, 271; 222/193, 389,
[56] References Cited UNITED STATES PATENTS 3,382,869 5/1968 Rigney et a1 128/130 3,604,417 9/1971 Stolzenberg 128/213 3,446,435 5/1969 Hager 222/389 X 2,962,023 11/1960 Chappaz et a1. 128/260 2,880,913 4/1959 Peyron 222/389 X 3,104,663 9/1963 Laws 128/224 [451 Sept. 25, 1973 Primary Examiner-Richard A. Gaudet Assistant ExaminerJ. C. McGowan Attorney-Steven D. Goldby and Paul L. Sabatine 5 7] ABSTRACT (3) a movable barrier member separating the first from I the second compartment. The barrier member is slidably responsive to an increase in volume in the second compartment via absorption of water by osmosis therein; whereby as water flows into the compartment (2) of the dispenser in a tendency towards osmotic equilibrium with its environment, corresponding pressure is exerted behind the barrier (3) driving it into and diminishing the volume of the compartment 1 in turn continuously ejecting active agent thereout at an osmotically controlled rate over a prolonged period of time.
14 Claims, 5 Drawing Figures HELICAL OSMOTIC DISPENSER WITH NON-PLANAR MEMBRANE CROSS REFERENCE TO RELATED APPLICATIONS Takeru Higuchi copending application, Ser. No. 106,131, filed Jan. 13, 1971, assigned to the assignee of the present invention; and
Takeru l-liguchi and Harold M. Leeper copending application, Ser. No. 106,130, filed Jan. 13, 1971, also assigned to the assignee of the present invention.
FIELD OF THE INVENTION This invention relates to an osmotic dispenser, and, more especially, to an osmotic dispenser, simple in construction, capable of releasing to its outside environment concentrations of active agent at an osmotically controlled rate over a prolonged period of time.
DEFINITION OF TERMS The expression active agent as used herein denotes any drug (as defined, infra); composition in any way affecting any biological entity; substance having a nutrient or stimulating action, or growth inhibiting, destroying or any regulating action on plant growth, controlled or otherwise; substance to beassimilated by any organism, e.g., human being, animal, or lower order organism, for its nourishment or for regulating its growth; substance exhibiting any of the above activities to be directly applied to the habitat, surroundings or environment of any of the above organisms; and substance having any other effect on any other environement, especially: any aqueous environment.
Therefore, suitable active agents for use with the dispenser of this invention include, without limitation, those which are generally capable of:
l. Preventing, alleviating, treating or curing abnormal and pathological conditions of the living body by such means as destroying a parasitic organism or limit ing the effect of the disease or abnormality by chemicallyaltering the physiology of the host or parasite;
2. Maintaining, increasing, decreasing, limiting or destroying a physiologic body or plant function, e. g., vitamin compositions-sex sterilants, fertility inhibitors, fertility promoters, growth promoters, and the like;
3. Diagnosing a physiological condition or state;
. 4. Controlling or protecting an environment or living body by attracting, disabling, inhibiting, killing, modifying, repelling or retarding an animal or microorganism, such as food and non-food baits, attractants and lures, biocides, pesticides, algicides, parasiticides, rodenticides, insecticides, fungicides, and the like;
5. Preserving, disinfecting or sterilizing; and
6. Controlling or affecting generically an environment, as by introducing a catalyst or metering a reactant into a reacting chemical system, or by effecting any chemical process therein, such as a fermentation, including propagation and/or attenuation of a microorganism.
The terms environment, surroundings and habitat as used hereinabove and herein denote any prospective situs for the osmotic dispenser of this invention which is comprised of or will provide sufficient water for absorption into the device to develop the needed osmotic pressure on which its motive'force depends; and implicit in the foregoing definition of active agent"-'- one that will develop its action in the presence of such environment, surroundings or habitat, or one that will develop its action in a remote and/or another environment, which need not be agueous, as hereinafter described and illustrated.
BACKGROUND OF THE INVENTION Many andva ried compositions, products, appliances, depositors, applicators, dispensers, injectors and devices are well known in the art in which the timing or spacing of administration or absorption of an active agent is regulated by the structure or physical arrangement of elements so that a single administration provides a gradual but continuous or sustained feeding of the active agent to a system by slow or differential release. All of such prior art devices and the like, however, are characterized by at least one feature which adversely affects control over their rate of sustained or differential release or which detracts from the practical benefits attendant the long term continuous administration of various active agents both to humans, animals, and into other environments.
An osmotic dispenser too has been proposed which is capable of delivering drug solution at a relatively constant rate. See Rose and Nelson, Austral, J. exp. BioL, 33 pp. 415 420 (1955). The Rose et al. injector consists of three compartments and a clamp to hold a semi-permeable membrane. The motive force of the injector depends on the osmotic pressure developed by a saturated aqueous solution of Congo red against water. This solution is contained in a partially collapsed rubber compartment and is separated from a second water compartment by the semipermeable cellophane membrane. The partially collapsed bag is placed in a glass ampoule, with the drug compartment of the device being defined by thefspace between the Congo red bag and the glass ampoule. The ampoule is also provided with drug release means and when the drug compartment is charged with a drug solution, by osmosis water will move into the Congo red solution thus expanding the rubber compartment and providing the mechanical force to eject the drug out of the apparatus.
The Rose et al, device, however, has substantial inherent disadvantages which has prevented its wide acceptance by the medical community. In the first place, the use of a solution as the drug vehicle 1. will not permit high concentration of drug to be embodied within the device; 2. such solutions exhibit the deleterious tendency to be released from the device by simple leaching, and 3. many chemical substances on prolonged storage in a dissolved state undergo chemical deterioration. The reference injector is moreover cumbersome in that it depends for its motive force on a separate water compartment rather than its environment. In addition, the Rose et a1, device is essentially only a research or experimentation tool, is complex in construction and is at least literally restricted to a Congo red solution to produce the osmotic driving force and to a cellophane osmotic membrane. See also Rose and Nelson, Austral. J. exp. Biol., 33 pp. 411 414 (1955).
SUMMARY OF THE INVENTION Accordingly, it is a primary object of this invention to provide an osmotic dispenser, simple in construction, which exhibits all of the practical benefits of longterm continuous administration of various active agents both to animals, humans, and into other environments.
Another object of this invention is to provide an improved osmotic dispenser which overcomes problems inherent in related devices heretofore proposed.
Another object of this invention is to provide an improved osomotic dispenser which will permit high concentrations of active agent to be embodied therein, and which high concentrations of active agent will not exhibit the tendency to be leached from the device, nor be decreased in potency by chemical breakdown.
Another object of this invention is to provide an osmotic active agent dispenser which depends for its motive force on its environment.
Still another object of this invention is to provide an osmotic dispenser, the osmotic membrane of which can be fabricated from many and varied suitable materials, and which is capable of using a variety of solutions of osmotically effective solutes to produce the osmotic driving force.
Yet another object of this invention is to provide an osmotic dispenser of simple design which will release active agent solution, or gel, or semisolid active agent formulation, at a controlled rate over a prolonged period of time.
In attaining the ob ects of this invention, one feature resides in an osmotic dispenser comprised of a first helical compartment of relatively impervious material containing an active agent and a second helical compartment containing a solution of an osmotically effective solute which exhibits an osmotic pressure gradient against water. The two helical compartments are interconnected so as to define a continuous helix. Separating the first helical compartment from the second helical compartment, and defining a wall member common to each of said compartments, is a sliding or movable barrier of impervious material, advantageously a plastic or glass ball separator. The enclosure, whether of integral construction or not, defining the remainder of the second compartment wherein the osmotic motive force of the dispenser is developed, is at least in part comprised of membrane material which exhibits controlled permeability to water. When placed in a hypotonic aqueous environment, water, by osmosis, is absorbed therefrom through the membrane and diffuses into the solution contained in the second compartment. As the water flows into the second compartment, the solution contained therein increases in volume exerting corresponding pressure behind the movable barrier divider. Such pressure serves to drive the said barrier forward and into the active agent compartment thus diminishing the volume of the same, and which sliding or rolling barrier in turn ejects the active agent out of the apparatus at an osmotically controlled rate over a prolonged period of time. For the purpose of permitting the active agent to be squeezed out of the first compartment, the same is provided at its terminal point with any suitable dispensing head or active agent release means to the exterior of the device, for example, a capillary duct therethrough.
A further feature of this invention resides in an osmotic active agent dispenser comprised of a dispenser according to the foregoing description enveloped by a relatively rigid, highly permeable housing member. The housing member serves both as a protective means for the dispenser and also to restrict expansion of the dispenser due to internal pressure. Alternatively, such expansion may be in and of itself restricted by means of any suitable band or tie member.
Other objects, features and advantages of this invention will become more apparent from the following description when taken in conjunction with the accompanying drawings and wherein like reference numerals are used to indicate like or equivalent parts.
BRIEF DESCRIPTION OF THE DRAWINGS In the drawings:
FIG. 1 is a fragmentary cross-sectional view of an osmotic dispenser of this invention;
FIG. 2 is a top view of FIG. 1;
FIG. 3 is a fragmentary cross-sectional view of a modification in the dispensing head of the osmotic dispenser of FIG. 1;
FIG. 3a is a fragmentary cross-sectional view of another modification in the dispensing head of the os-' motic dispenser of FIG. 1; and
FIG. 4 is a fragmentary cross-sectional view of an osmotic dispenser of this invention having a rigid housing member.
DETAILED DESCRIPTION OF THE INVENTION In one embodiment in accordance with this invention, as illustrated in FIG. 1, anosmotic dispenser 10 is comprised of two helically shaped compartments, a first compartment designated generally byreference numeral 12 and the second compartment designated byreference numeral 14. Each of the helical compartments is formed by coiling a relatively flexible tubular material, the former essentially being a continuation of the latter, although, as hereinafter described, there are significant differences in the types and properties of the tubular material used to fabricate each of the helical compartments l2 and 14. The lower end or terminal point ofcompartment 14 is sealed off, as, for example, bycurved plug member 16 of a rigid impervious material such as refractory plastic. Optionally,plug member 16 may be fabricated from metal or similar heavy material to additionally serve as a ballast member for adjusting the specific gravity of the dispenser. The terminal point ofhelical compartment 12 is provided with a short continuation in the form oftubing 18 having a capillary duct or opening 20 approximately 0.5 millimeters in diameter. Joints between the respective components may be press-fits or may involve use of an adhesive system. The device is preferably provided with one or more bands orties 22 which bind together each of the coils in the helix and act as restraining means to prevent spreading of the coils due to internal pressures developed in the dispenser. A slidingbarrier plug 24 of impermeable material compartmentalizes the helix and thus defines the exact boundaries of thehelical compartments 12 and 14.
Thefirst compartment 12 contains the active agent, advantageously a drug, in a gel, paste or other semisolid state (albeit a solution or concentrated solution of active agent will sometimes suffice), and the active agent, if a drug, is preferably normally carried in an oil phase, such as cocoa butter.Compartment 12 is thus fabricated from a material which is impermeable both to the drug contained therein and also to all components of the dispenser environment.
Thesecond compartment 14 contains a solution of an osmotically efiective solute which exhibits an osmotic pressure gradient against water; and the slidingbarrier plug 24 is so constructed as to movably provide and maintain a tight barrier between the active agent phase in the first compartment and the osmotic fluid in the second compartment. Advantageously, and as illustrated, the barrier is a plastic or glass ball separator. Without this tight barrier, undesirable contamination could take place.Compartment 14 is fabricated at least in part from a material which exhibits controlled permeability to water, preferably a semi-permeable membrane of the type used in reverse osmosis water desalination, e.g., isotropic or anisotropic cellulose acetate. Obviously, the tubing used to fabricatecompartment 14 must be impermeable to the osmotically active solute contained therein.
The capillary tube or active agent release means 18 provides communication from the interior of thecompartment 12 to the exterior of thedevice 10, in this instance the said means being comprised ofcapillary duct 20 formed at the tenninal point of the active agent containinghelical compartment 12. See also FIG. 2. Theplug 24 is frictionally disposed but is free to move within the device by sliding while at the same time maintaining an impenetrable or contamination preventing barrier between the active agent phase and the osmotic fluid. Thus, an oil/water or other interface can be said to exist at the point of the plug in the device.
To use the osmotic active agent dispenser of FIG. 1, the device, when the active agent is a drug or other agent for treating, etc., a living organism, is either physically inserted or surgically implanted in the body of the organism, typically a mammal, or is administered via the gastrointestinal tract. Once in place, water will be absorbed therein from either body tissues or body fluids through the water permeable walls ofcompartment 14 in an effort to reach osmotic equilibrium, i.e., a transition from hypertonicity to isotonicity. As the water flows into thecompartment 14 tending to increase the volume of same corresponding pressure is built up behind the slidingbarrier plug 24. Such pressure serves to drive the said barrier plug 24 forward at a constant rate thus forcing the drug through thetube 18 andcapillary duct 20 at an osmotically controlled and constant rate into the external environment. There is accordingly provided the gradual and controlled constant release of drug or similar agent directly to the body or affected organ thereof over a prolonged period of time. Moreover, the use of any semisolid drug vehicle will reduce the tendency to release the drug, or any other active agent for that matter, by leaching and will permit high concentrations thereof to be embodied within the device.
In some instances, the dispenser is of insufficient specific gravity to maintain placement at the desired location. For example, for use in the rumen of polygastric animals, the weight should be sufficient to provide a specific gravity of at least 1.5. In those instances of insufficient specific gravity, therefore, a weight or ballast can be placed in the device, such as themetal plug 16 in FIG. 1. Suitable weights comprise steel plugs, iron plugs, brass plugs, ceramic plugs, or the like.
' When the active agent is other than a drug or similar agent, or is intended for use other than in a living organism, the device is introduced into the desired aqueous environment to produce the desired affect exactly as would be any of the known means for accomplishing v a like result. And this is generally a mere physical insertion, such as by placing a pesticide containing device in a river or stream or a catalyst containing device in an aqueous reaction medium.
If desired, long flexible tubing of polythene or th like can be extended from the dispensing head of the device of FIG. I. In such a configuration, as illustrated in FIG. 3, the device can be deposited at a site remote from the desired point of application and still release its active agent contents through the dispensing head and then through the tube directly to said point. This permits placement of the dispenser in an aqueous environment and release of the active agent into another environment which need not be aqueous. The dispensing head can also be provided with a check valve, for example, a one way ball valve (see FIG. 3a), to prevent backflow of active agent or other materials from the external environment'into the device.
The design of a device in accordance with the present invention is moreover unique in that it provides a simple means to control the amount of surface area available for osmotic penetration. Thus, for example, by decreasing the diameter of the tubing used to manufacture the helical coils, or by increasing the number of turns in the helix of compartment 14 a significant increase in the surface area of the water-permeable material results, whereby such a design provides for ready attainment of large exposure areas of the water permeable membrane and thus takes advantage of the availability of a far greater number of water-permeable materials than the semi-permeable, anisotropic cellulose acetate membrane of the type used in reverse osmosis water desalination. Isotropic membranes have less water permeability than do the anisotropic membranes. Use of the latter type of material, however, permits significant decreases in the size ofhelical compartment 14.
In FIG. 4 there is depicted an osmotic active agent dispenser generally of the type illustrated in FIG. 1, except that the same is enveloped by a relatively rigidpermeable housing member 26. The porosity of the housing member readily permits contact of water from the environment with the dispensing device, while at the same time its relatively rigid characteristics afford a high degree of protection from damage or puncturing to the dispenser. Moreover, the housing member advantageously serves as a restraining means to prevent spreading of the coils, etc., in the device due to internal pressure, especially when a housing member having both ends capped is provided for this purpose; and serves the furter purpose of facilitating emplacement in a given host or environment.
Another salient feature of the osmotic active agent dispenser of this invention resides in its simple means of construction, and correlatively in the simple manner thereby provided for controlling the dosage rate in a given dispenser device. In contradistinction to other known types of active agent dispensing devices wherein a device of different size is required for each dosage level to be contained therein, the instant dispensing device may be designed to contain and administer any desired quantity of active agent to contain and administer any desired quantity of active agent by merely increasing or decreasing the length of tubing which constitutes the active agent containinghelical compartment 12.
Moreover, a device according to this invention is admirably suited for the continuous administration of the antibiotic oxytetracycline to beef cattle from the rumen. This because such devices can easily be fabricated of a size, weight and shape as to be retained in the rumen of polygastric animals to release drug or similar agents thereto at a carefully controlled rate. Other variations of the basic theme would be readily apparent to the skilled artisan. Although particular configurations may be designed for specific body uses, each of these configurations is applicable to use in other environments.
The tubing employed to fabricate the osmoticsolution containing compartment 14 can be formed from the wide variety of materials permeable or semipermeable to solvent (water) but not to solute, i.e., those suitable for the construction of an osmotic cell. For best results, the material should be substantially impermeable to passage of the osmotically effective solute so as to prevent losses thereof. Same is also insoluble and chemically compatible with the salt solution in thecompartment 14. Typical membranes are isotropic membranes such as unplasticized cellulose acetate, plasticized cellulose acetate, reinforced cellulose acetate, cellulose diand triacetate, ethyl cellulose; anisotropic reverse osmosis membranes which typically are made of cellulose acetate; silicone rubbers, polyurethanes, natural rubber, and hydrolyzed ethylene/vinyl acetate copolymers. Isotropic membranes such as above have less water permeability than do the anisotropic membranes. Also, with both types of materials, increasing the acetate content of the cellulose acetate polymer decreases the water permeability. Since, as previously described, the surface area available for osmotic transfer may be widely varied, the devices of this invention are not limited to any one class of water permeable material, i.e., both those exhibiting high permeability as well as those of lower permeability may be employed. Thus, a cellulose acetate membrane suitable for a device designed with limited surface area available for osmotic transfer is Eastman Chemical Products Type R 97, which is rated to be permeable to 1.5 to 2 cc/cm /day at atmospheric pressure, against a saturated solution of K 80 at 39 C. When the compartment is fabricated from an anisotropic reverse osmosis type of membrane it is possible to obtain a delivery rate of from to 10,000 mg of active agent per day. In genera], the unplasticized membranes of whatever type provide for a far greater rate of release per day than do the plasticized membranes. The device of the above specific embodiment, having a specific gravity of at least L5, is moreover well suited for administration to the rumen of beef cattle, whereat it is retained, via the gastrointestinal tract; and this is an excellent way of treating, for example, a 500 pound calf with anti-biotic. For drug depot applications as heretofore described, the membranes are also biologically inert, nonirritating to body tissues and non-allergenic. One specific embodiment of a dispenser fabricated in accordance with the design illustrated in FIG. 1, havingcompartment 14 fabricated of cellulose diacetate tubing (degree of acetyl substitution 2.4) andcompartment 12 formed of polyethylene tubing, and having the following dimensions:
Compartment l4 Compartment 12 Outer diameter of tubing 1.000 cm 0.976 cm Wall thickness 0.012 cm 0.050 cm Inner diameter of tubing 0.976 cm 0.876 cm Outer diameter of helix 3 cm 3 cm Number of turns 4 3 Uncoiled length 25.l cm 18.8 cm Initial volume Osmotic Solution l8.75 cc Saturated aqueous solution of NaCl containing sufficient excess solute in solid form to maintain solution saturated over period of intended use.
Compartment l4 Compartment 12 Initial volume drug 11.3 cc Effective surface area 78.9 cm Final volume osmotic solution 30.0 cc Final volume drum 0.00 cc Overall size of device:
Diameter 3.2 cm Height 7.5 cm
Approximately 55 percent oxytetracycline hydrochloride in 45 percent cocoa butter medium.
is capable of delivering 20 to 300 mg of drug per day.
The impermeable plastic material used to fabricatecompartment 12 of the device too is insoluble, is chemically compatible with the active agent contained therein, and can be formed of polystyrene, polyethylene, polypropylene, polyethylene terephthalate, polyvinyl chloride, reinforced epoxy resin, polymethylmethacrylate, etc., metal foil polyethylene laminate, neoprene rubber, natural gum rubber, rubber hydrochloride, sheet metal, galvanized pipe, or styrene/acrylonitrile copolymer. It is of course intended that such casing or shell act as a barrier to the transport of water. Again, for drug depot applications, the same are advantageously biologically inert, non-irritating to body tissues and non-allergenic. The barrier plug 24 can be formed of materials identical to those used for fabricating the impervious activeagent containing compartment 12, and additionally can be formed of glass. Likewise with respect to therigid housing member 26 of FIG. 4, except in this instance the materials would be highly porous since it is not intended that the housing member in any way act as a barrier to or restrict the transport of water.
Many other materials including those which are biologically acceptable are suitable for fabrication of the several component parts of the device of this invention. While the said several component parts of the device of the invention have previously been described as being insoluble under the conditions and in the environment of intended use, it is also within the scope of the invention that such materials be insoluble only during the period of said intended use; thereafter dissolving away in the environment of the device. Thus, a dispenser is here contemplated which is unaffected by its environment, solubility-wise, at the situs of use, or which is only slightly soluble during the period of intended use, such that once its active agent content has been discharged it will then dissolve or erode away leaving no objectionable residue or empty container at the said situs of use.
It is further within the scope of the invention to optionally provide the subject dispenser with a selfcontained water supply or separate water compartment, as in the first mentioned Rose and Nelson publication, supra.
The relative wall thicknesses of the various types of tubing comprising the two compartments of the dispeners of the invention can vary widely and are not limitations on the invention. Typically, however, the impermeable tubing ofcompartment 12 has a wall thickness of 0.5 to 50 mils, preferably of 5 to 50 mils, and the water permeable tubing ofcompartment 14 has a wall thickness of 1 to 10 mils.
Any of the drugs used to treat the body, both topical and systemic, can be compartmentalized as the active agent in any of the osmotic dispensers of this invention. Drug" is used herein in its broadest sense as including any composition of substance that will produce a pharmacological or biological response.
Suitable drugs for use in therapy with the dispenser of the invention include without limitation:
1. Protein drugs such as insulin;
2. Desensitizing agents such as ragweed pollen antigens, hay fever pollen antigens, dust antigen and milk antigen;
3. Vaccines such as small pox, yellow fever, distemper, hog cholera, fowl pox, antivenom, scarlet fever, dyphtheria toxoid, tetanus toxoid, pigeon pox, whooping cough, influenzae, rabies, mumps, measles, poliomyelitis, Newcastle disease, etc.;
4. Anti-infectives, such as antibiotics, including penicillin, tetracycline, chlortetracycline, bacitracin, nystatin, streptomycin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin; sulfonamides, including sulfacetamide, sulfamethizole, sulfamethazine, sulfadiazine, sulfamerazine, and sulfisoxazole; anti-virals including idoxuridine; and other anti-infectives including nitrofurazone and sodium propionate;
5. Anti-allergenics such as antazoline, methapyrilene, chlorpheniramine, pyrilamine and prophenpyridamine;
6. Anti-inflammatories such as hydrocortisone; cortisone, hydrocortisone acetate, dexamethasone, dexamethasone 2l-phosphate, fluocinolone, triamcinolone, .medrysone, prednisolone, prednisolone 2l-phosphate, and prednisolone acetate;
7. Decongestants such as phenylephrine, naphazoline, and tetrahydrozoline;
8. Miotics and anticholinesterases such as pilocarpine, eserine salicylate, carbachol, di-isopropyl flurophosphate, phospholine iodide, and demercarium bromide;
9. Mydriatics such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, and hydroxyamphetamine;
l0. Sympathomimetics such as epinephrine;
ll. Sedatives and Hypnotics such as pentobarbital sodium, phenobarbital, secobarbital sodium, codeine, (a-bromoisovaleryl) urea, carbromal;
l2. Psychic Energizers such as 3-(2-aminopropyl) indole acetate and 3-(2-aminobutyl) indole acetate:
l3. Tranquilizers such as reserpine, chlorpromazine, and thiopropazate;
l4. Androgenic steroids such as methyltestosterone and fluoxymesterone;
l5. Estrogens such as estrone, l7 Bestradiol, and diethyl stilbesterol;
l6. Progestational agents such as progesterone, megestrol, melengestrol, chlormadinone, ethisterone, norethynodrel, l9-nor-progesterone, norethindrone, medroxyprogesterone and 17 a-hydroxy-progesterone;
l7. Humoral agents such as the prostaglandins, for example, PGE PGE and PGF l8. Antipyretics such as aspirin, sodium salicylate, and salicylamide;
l9. Antispasmodics such as atropine, methantheline, papaverine, and methscopolamine bromide;
20. Anti-materials such as the 4-aminoquinolines, 8- aminoquinolines, chloroquine, and pyrimethamine;
21. Antihistamines such as diphenhydramine, dimenhydrinate', tripelennamine, perphenazine, and carphenazine;
22. Cardioactive agents such as hydrochlorothiazide, flumethiazide, chlorothiazide, and trolnitrate;
23. Nutritional agents such as vitamins, essential 'amino acids and essential fats;
vention. Suitable mixtures of drugs can, of course, be
dispensed with equal facility as with single component systems.
Drugs can be in various forms, such as uncharged molecules, components of molecular complexes, or non-irritating pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulphate, phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc. For acidic drugs, salts of metals, amines, or organic cations (e.g., quaternary ammonium) can be employed. Furthermore, simple derivatives of the drugs (such as ethers, esters, amides, etc.) which have desirable retention and release characteristics but which are easily hydrolyzed by body pl-l, enzymes, etc., can be employed.
The amount of drug incorporated in the osmotic dispenser varies widely depending on the particular drug, the desired therapeutic effect, and the time span for which it takes the drug to be released. Since a variety of dispensers in a variety of sizes and shapes are intended to provide complete dosage regimes for therapy for a variety of maladies, there is no critical upper limit on the amount of drug incorporated in the dispenser. The lower limit too will depend on the activity of the drug and the time span of its release from the dispenser. Thus it is not practical to define a range for the therapeutically effective amount of drug to be released by the dispenser.
The motive force of the dispenser of this invention depends on the osmotic pressure generated by the solution of the osmotically effective solute contained in thecompartment 14, which solution exhibits an osmotic pressure gradient against water. Said solution is most preferably a saturated aqueous salt solution. To maintain the solution saturated and therefore to achieve a constant osmotic pressure throughout operation of the dispenser, the compartment containing the solution also contains excess solute in solid form. Various osmotically effective solutes can be used. These include magnesium sulphate, magnesium chloride, sodium -chloride, potassium sulphate, sodium carbonate, so-
dium sulphite, sodium sulphate, sodium bicarbonate, potassium acid phthalate, calcium bicarbonate, potassium acid phosphate, raffinose, tartaric acid, succinic acid, calcium succinate, calcium lactate, and magnesium succinate. The excess solid solute can be in the I form of dispersed particles or preferably in the form of a pellet. The solution can initially be a solution of the same or of a osmotically effective solute different than the solid excess solute.
The osmotic dispenser can be fabricated in any convenient shape for either physical insertion or implantation in the body, or for administration via the gastrointestinal tract, or for introduction into any desired environment. Dimensions of the device can thus vary widely and are not of controlling importance. The lower limit of the size of the device is governed by the amount of the particular active agent to be supplied to the environment to elicit the desired response, as well as by the form the dosage unit takes, for example, in
cases of specific body uses, implantate, bolus, IUD, lVD, vaginal ring, uterine capsule for fertility suppression, artificial gland, pessary, prosthesis, suppository, and the like. Likewise with respect to the upper limit on the size of the device. In one specific embodiment, the dispenser can be of such size as to deliver 1 to 2 cc of drug formulation per day and to deliver a total of 5 to cc of drug formulation over a 5 to 10 day period. With alternate choice of slower permeation materials, the pump can deliver drug more slowly up to and in excess of one year. It is preferred that the construction of the several compartments and of the active agent release means be such that the osmotic driving pressure developed is at least 10 times greater than the back pressure generated by the active agent formulation.
Thus, the invention provides, in an osmotic dispenser, a reliable means for releasing effective concentrations of active agent contained therein to the body of a living organism, or to any other environment, at an osmotically controlled rate and over a prolonged period of time. In addition, prime advantages of the dispenser of the invention are that it is simple in construction and exhibits all of the practical advantages of the long-term continuous administration of various active agents both to humans, animals, and into other environments, and that the active agent contained therein will not exhibit the tendency to be leached therefrom.
While the invention has been described and illustrated with reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various modifications, changes, omissions, and substitutions can be made without departing from the spirit of the invention. It is intended, therefore, that the invention be limited only by the scope of the following claims.
What is claimed is:
1. An osmotic active agent dispenser comprising, (1 a first helical compartment of relatively impervious material containing an active agent and provided with means for releasing said active agent to the exterior of the dispenser; (2) a second helical compartment comprised of membrane material having controlled permeability to water, being at least in part non-planar in configuration, and containing an osmotically effective solute which, in solution, exhibits an osmotic pressure gradient against water, said second compartment being interconnected with said first compartment to define a continuous helix therewith; means to restrict substantial expansion of the helix due to internal pressure and (3) a movable barrier member separating the said first from the said second compartment and movably responsive to an increase in volume in the said second compartment via absorption of water by osmosis therein; whereby as water flows into the compartment (2) of the dispenser in a tendency towards osmotic equilibrium with its environment, corresponding pressure is exerted behind the barrier (3) driving same into and diminishing the volume of the compartment l in turn continuously ejecting active agent thereout at an osmotically controlled rate over a prolonged period of time.
2. The osmotic dispenser as defined by claim 1, wherein the barrer (3) defines a wall member common to each of said compartments (1) and (2).
3. The osmotic dispenser as defined by claim 1, wherein the active agent is selected from the group consisting of a drug and a bio-affecting composition.
4. The osmotic dispenser as defined by claim 1, wherein the active agent contained therein is in the form of a semisolid formulation.
5. The osmotic dispenser as defined by claim 1, wherein the solution exhibiting an osmotic pressure gradient against water is a saturated aqueous salt solution.
6. The osmotic dispenser as defined by claim 5, wherein the saturated salt solution contains excess solute in solid form.
7. The osmotic dispenser as defined by claim 1, wherein the first helical compartment (1) is comprised of a member selected from the group consisting of polyethylene, metal-foil polyethylene laminate, neoprene rubber, rubber hydrochloride, polystyrene, polypropylene, polyethylene terephthalate, polyvinlyl chloride, polymethylmethacrylate, sheet metal, galvanized pipe, reinforced epoxy resin, natural gum rubber, and styreneacrylonitrile copolymer.
8. The osmotic dispenser as defined by claim 1, wherein the second helical compartment (2) is comprised of a member selected from the group consisting of cellulose acetate, silicone rubber, polyurethane, natural rubber and hydrolyzed ethylene/vinyl acetate copolymer.
9. The osmotic dispenser as defined by claim 1, wherein the active ingredient release means comprises a capillary tube forming an extension of helical compartment (1).
10. The osmotic dispenser as defined by claim 1, wherein the restricting means comprises a relatively rigid permeable housing member enveloping the device.
11. The osmotic dispenser as defined byclaim 10, wherein the housing member is comprised of a member selected from the group consisting of perforated polystyrene, perforated polyethylene, perforated polypropylene, perforated polyethylene terephthalate, perforated polyvinyl chloride, perforated polymethylmethacrylate, perforated sheet metal, perforated reinforced epoxy resin, perforated galvanized pipe, porous sintered brass tubing, porous styrene/acrylonitrile polymer, and porous sintered polyethylene.
12. The osmotic dispenser as defined by claim 1, wherein the movable impervious barrier is a spherical body comprised of glass or plastic.
13. The osmotic dispenser as defined by claim 1, further comprising a ballast member to regulate the weight thereof.
14. The osmotic dispenser as defined by claim 1, wherein the osmotically effective solute is selected from the group consisting of magnesium sulphate, magnesium chloride, sodium chloride, potassium sulphate, sodium carbonate, sodium sulfite, sodium sulphate, sodium bicarbonate, potassium acid phthalate, calcium bicarbonate, potassium acid phosphate, raffinose, tartaric acid, succinic acid, calcium succinate, calcium lactate, magnesium succinate and mixtures thereof.

Claims (13)

US00106132A1971-01-131971-01-13Helical osmotic dispenser with non-planar membraneExpired - LifetimeUS3760806A (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US10613271A1971-01-131971-01-13

Publications (1)

Publication NumberPublication Date
US3760806Atrue US3760806A (en)1973-09-25

Family

ID=22309665

Family Applications (1)

Application NumberTitlePriority DateFiling Date
US00106132AExpired - LifetimeUS3760806A (en)1971-01-131971-01-13Helical osmotic dispenser with non-planar membrane

Country Status (2)

CountryLink
US (1)US3760806A (en)
JP (1)JPS4894575A (en)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3880164A (en)*1972-05-221975-04-29Alza CorpOsmotic wound drain
US4034756A (en)*1971-01-131977-07-12Alza CorporationOsmotically driven fluid dispenser
US4036227A (en)*1973-04-251977-07-19Alza CorporationOsmotic releasing device having a plurality of release rate patterns
US4077407A (en)*1975-11-241978-03-07Alza CorporationOsmotic devices having composite walls
US4177256A (en)*1973-04-251979-12-04Alza CorporationOsmotic bursting drug delivery device
US4243030A (en)*1978-08-181981-01-06Massachusetts Institute Of TechnologyImplantable programmed microinfusion apparatus
EP0179518A1 (en)*1984-10-161986-04-30Akzo N.V.IUD extractor thread
US4662879A (en)*1984-09-151987-05-05Stc PlcRumen bolus
US4680172A (en)*1985-03-051987-07-14Ciba-Geigy CorporationDevices and methods for treating memory impairment
US4723958A (en)*1986-05-231988-02-09Merck & Co., Inc.Pulsatile drug delivery system
US4765985A (en)*1985-03-051988-08-23Ciba-Geigy CorporationDevices and methods for treating memory impairment
US4871542A (en)*1987-04-301989-10-03Ferring Service Center, N.V.Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract
US5209746A (en)*1992-02-181993-05-11Alza CorporationOsmotically driven delivery devices with pulsatile effect
US5299581A (en)*1990-07-051994-04-05Donnell John TIntravaginal device
US5308348A (en)*1992-02-181994-05-03Alza CorporationDelivery devices with pulsatile effect
US5456679A (en)*1992-02-181995-10-10Alza CorporationDelivery devices with pulsatile effect
US5582591A (en)*1994-09-021996-12-10DelabDelivery of solid drug compositions
US5660846A (en)*1994-09-021997-08-26Societe De Conseils De Recherches Et D'applications ScientifiquesMethods and apparatus for the delivery of solid drug compositions
US5897530A (en)*1997-12-241999-04-27Baxter International Inc.Enclosed ambulatory pump
US5972369A (en)*1997-03-311999-10-26Alza CorporationDiffusional implantable delivery system
US6114347A (en)*1993-12-102000-09-05Lts Lohmann Therapie-Systeme GmbhPharmaceutical formulation for the prophylaxis and pretreatment of a poisoning caused by organophosphorus cholinesterase inhibitors
US6136013A (en)*1996-09-182000-10-24Owen Mumford LimitedLancet device
US6554792B2 (en)*1999-05-212003-04-29Mallinckrodt Inc.Suspension device and method
US6627631B1 (en)*1999-02-192003-09-30Lts Lohmann Therapie-Systeme AgPharmaceutical composition containing desoxypeganine for the treatment of alcoholism
US20030191453A1 (en)*2002-04-032003-10-09Velez Omar E.Catheter assembly
US20040159324A1 (en)*1995-06-072004-08-19Conceptus, Inc.Contraceptive transcervical fallopian tube occlusion devices and their delivery
US20040260271A1 (en)*2003-06-182004-12-23Huyser Richard F.Extended fenestration catheter with internal coil and method of making the same
US20040260242A1 (en)*1999-05-212004-12-23Mallinckrodt Inc.Suspension device and method
US20050175701A1 (en)*2004-02-102005-08-11Alza CorporationCapillary moderator for osmotic delivery system
US20050172972A1 (en)*1995-06-072005-08-11Conceptus, Inc.Contraceptive transcervical fallopian tube occlusion devices and methods
US20070023534A1 (en)*2005-07-222007-02-01Mingsheng LiuWater-source heat pump control system and method
US20070149954A1 (en)*2005-11-092007-06-28Searete Llc., A Limited Liability Corporation Of The State Of DelawareAcoustically controlled substance delivery device
US20080140057A1 (en)*2006-03-092008-06-12Searete Llc, A Limited Liability Corporation Of State Of The DelawareInjectable controlled release fluid delivery system
US20080177126A1 (en)*2007-01-012008-07-24Tate Leon JRadiopharmaceutical administration methods, fluid delivery systems and components thereof
US20090005727A1 (en)*2006-03-092009-01-01Searete LlcAcoustically controlled substance delivery device
US20090162249A1 (en)*2006-03-092009-06-25Searete LlcAcoustically controlled reaction device
US20100030185A1 (en)*2006-01-182010-02-04Searete LlcRemote controller for substance delivery system
US20100076415A1 (en)*2005-11-092010-03-25Searete LlcRemote control of substance delivery system
GB2446100B (en)*2005-11-092011-11-02Searete LlcRemote controlled in vivo reaction method
US8109923B2 (en)2005-12-132012-02-07The Invention Science Fund I, LlcOsmotic pump with remotely controlled osmotic pressure generation
US20120203264A1 (en)*2011-01-212012-08-09Endologix, Inc.Graft Systems Having Semi-Permeable Filling Structures and Methods for Their Use
WO2013064745A1 (en)*2011-11-012013-05-10Bayer OyOsmotically active vaginal delivery system
US9067047B2 (en)2005-11-092015-06-30The Invention Science Fund I, LlcInjectable controlled release fluid delivery system
US9108047B2 (en)2010-06-042015-08-18Bayer Medical Care Inc.System and method for planning and monitoring multi-dose radiopharmaceutical usage on radiopharmaceutical injectors
US9296757B2 (en)2012-05-212016-03-29Bayer Pharma AktiengesellschaftSubstituted benzothienopyrimidines
US9382255B2 (en)2012-09-202016-07-05Bayer Pharma AktiengesellschaftSubstituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
JPS5836370Y2 (en)*1981-01-131983-08-16公明 中川 Giyoza grill machine
JPH0483135U (en)*1990-11-291992-07-20
JP2002223950A (en)*2001-01-292002-08-13Owada Seisakusho:KkMachine and cooking method for spit-roasting
ITUD20110159A1 (en)*2011-10-072013-04-08M E G I C Pizza Ciacolada S A S D I Acampora Ger DEVICE FOR THE FORMING AND COOKING OF A FOAMED OVEN FOOD PRODUCT, FILLED PIZZA TYPE

Citations (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US2880913A (en)*1957-05-311959-04-07Francois A PeyronTubes for dispensing pastes, creams and the like
US2962023A (en)*1955-10-281960-11-29Chappaz GastonMedicator
US3104663A (en)*1960-02-031963-09-24Birch And BirchPressurized means for body cavity treatment
US3382869A (en)*1966-02-021968-05-14Ortho Pharma CorpIntrauterine contraceptive device
US3446435A (en)*1967-06-191969-05-27Moog IncExpulsion device having floating piston
US3604417A (en)*1970-03-311971-09-14Wayne Henry LinkenheimerOsmotic fluid reservoir for osmotically activated long-term continuous injector device

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US2962023A (en)*1955-10-281960-11-29Chappaz GastonMedicator
US2880913A (en)*1957-05-311959-04-07Francois A PeyronTubes for dispensing pastes, creams and the like
US3104663A (en)*1960-02-031963-09-24Birch And BirchPressurized means for body cavity treatment
US3382869A (en)*1966-02-021968-05-14Ortho Pharma CorpIntrauterine contraceptive device
US3446435A (en)*1967-06-191969-05-27Moog IncExpulsion device having floating piston
US3604417A (en)*1970-03-311971-09-14Wayne Henry LinkenheimerOsmotic fluid reservoir for osmotically activated long-term continuous injector device

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Govidan and Sourirajan, Reverse Osmosis Separation of Some Inorganic Salts ... Using...Membranes; I & EC Process Design and Development, Vol. 5, No. 4, Oct. 1966; p. 422 429.*

Cited By (95)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4034756A (en)*1971-01-131977-07-12Alza CorporationOsmotically driven fluid dispenser
US3880164A (en)*1972-05-221975-04-29Alza CorpOsmotic wound drain
US4036227A (en)*1973-04-251977-07-19Alza CorporationOsmotic releasing device having a plurality of release rate patterns
US4177256A (en)*1973-04-251979-12-04Alza CorporationOsmotic bursting drug delivery device
US4077407A (en)*1975-11-241978-03-07Alza CorporationOsmotic devices having composite walls
US4243030A (en)*1978-08-181981-01-06Massachusetts Institute Of TechnologyImplantable programmed microinfusion apparatus
US4662879A (en)*1984-09-151987-05-05Stc PlcRumen bolus
EP0179518A1 (en)*1984-10-161986-04-30Akzo N.V.IUD extractor thread
US4680172A (en)*1985-03-051987-07-14Ciba-Geigy CorporationDevices and methods for treating memory impairment
US4765985A (en)*1985-03-051988-08-23Ciba-Geigy CorporationDevices and methods for treating memory impairment
US4723958A (en)*1986-05-231988-02-09Merck & Co., Inc.Pulsatile drug delivery system
US4871542A (en)*1987-04-301989-10-03Ferring Service Center, N.V.Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract
US5299581A (en)*1990-07-051994-04-05Donnell John TIntravaginal device
US5209746A (en)*1992-02-181993-05-11Alza CorporationOsmotically driven delivery devices with pulsatile effect
US5308348A (en)*1992-02-181994-05-03Alza CorporationDelivery devices with pulsatile effect
US5456679A (en)*1992-02-181995-10-10Alza CorporationDelivery devices with pulsatile effect
US6114347A (en)*1993-12-102000-09-05Lts Lohmann Therapie-Systeme GmbhPharmaceutical formulation for the prophylaxis and pretreatment of a poisoning caused by organophosphorus cholinesterase inhibitors
US5660846A (en)*1994-09-021997-08-26Societe De Conseils De Recherches Et D'applications ScientifiquesMethods and apparatus for the delivery of solid drug compositions
US5582591A (en)*1994-09-021996-12-10DelabDelivery of solid drug compositions
US5837276A (en)*1994-09-021998-11-17DelabApparatus for the delivery of elongate solid drug compositions
US6306420B1 (en)1994-09-022001-10-23Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.Methods and apparatus for the delivery of solid drug compositions
US6142972A (en)*1994-09-022000-11-07DelabMethod and apparatus for the delivery of elongate solid drug compositions
US5616123A (en)*1994-09-021997-04-01DelabDelivery of solid drug compositions
US8171936B2 (en)1995-06-072012-05-08Conceptus, Inc.Contraceptive transcervical fallopian tube occlusion devices and methods
US20050172972A1 (en)*1995-06-072005-08-11Conceptus, Inc.Contraceptive transcervical fallopian tube occlusion devices and methods
US8733361B2 (en)1995-06-072014-05-27Bayer Essure Inc.Occlusion devices and methods
US20070062542A1 (en)*1995-06-072007-03-22Nikolchev Julian NContraceptive transcervical fallopian tube occlusion devices and methods
US8356599B2 (en)1995-06-072013-01-22Conceptus, Inc.Occlusion devices and methods
US8327852B2 (en)1995-06-072012-12-11Conceptus, Inc.Occlusion devices and methods
US20040163651A1 (en)*1995-06-072004-08-26Conceptus, Inc.Transcervical fallopian tube occlusion devices and their delivery
US7428904B2 (en)1995-06-072008-09-30Alien Technology CorporationContraceptive transcervical fallopian tube occlusion devices and their delivery
US20040159324A1 (en)*1995-06-072004-08-19Conceptus, Inc.Contraceptive transcervical fallopian tube occlusion devices and their delivery
US8066007B2 (en)1995-06-072011-11-29Conceptus, Inc.Contraceptive transcervical fallopian tube occlusion devices and their delivery
US7921848B2 (en)1995-06-072011-04-12Conceptus, Inc.Contraceptive transcervical fallopian tube occlusion devices and methods
US7686020B2 (en)1995-06-072010-03-30Conceptus, Inc.Contraceptive transcervical fallopian tube occlusion devices and methods
US6136013A (en)*1996-09-182000-10-24Owen Mumford LimitedLancet device
US5972369A (en)*1997-03-311999-10-26Alza CorporationDiffusional implantable delivery system
US8613282B2 (en)1997-09-242013-12-24Conceptus, Inc.Occlusion devices and methods
US8733360B2 (en)1997-09-242014-05-27Bayer Essure Inc.Occlusion devices and methods
US5897530A (en)*1997-12-241999-04-27Baxter International Inc.Enclosed ambulatory pump
US6627631B1 (en)*1999-02-192003-09-30Lts Lohmann Therapie-Systeme AgPharmaceutical composition containing desoxypeganine for the treatment of alcoholism
US6554792B2 (en)*1999-05-212003-04-29Mallinckrodt Inc.Suspension device and method
US20030105423A1 (en)*1999-05-212003-06-05Mallinckrodt Inc.Suspension device and method
US20040260242A1 (en)*1999-05-212004-12-23Mallinckrodt Inc.Suspension device and method
US20030191453A1 (en)*2002-04-032003-10-09Velez Omar E.Catheter assembly
US20040260271A1 (en)*2003-06-182004-12-23Huyser Richard F.Extended fenestration catheter with internal coil and method of making the same
WO2005077334A1 (en)*2004-02-102005-08-25Alza CorporationCapillary moderator in an osmotic delivery system for preventing backflow into the active agent reservoir
US20050175701A1 (en)*2004-02-102005-08-11Alza CorporationCapillary moderator for osmotic delivery system
US20070023534A1 (en)*2005-07-222007-02-01Mingsheng LiuWater-source heat pump control system and method
US8998884B2 (en)2005-11-092015-04-07The Invention Science Fund I, LlcRemote controlled in situ reaction method
US9254256B2 (en)2005-11-092016-02-09The Invention Science Fund I, LlcRemote controlled in vivo reaction method
US8992511B2 (en)2005-11-092015-03-31The Invention Science Fund I, LlcAcoustically controlled substance delivery device
US8968274B2 (en)2005-11-092015-03-03The Invention Science Fund I, LlcAcoustically controlled substance delivery device
US8114065B2 (en)2005-11-092012-02-14The Invention Science Fund I, LlcRemote control of substance delivery system
US8172833B2 (en)2005-11-092012-05-08The Invention Science Fund I, LlcRemote control of substance delivery system
US20100076415A1 (en)*2005-11-092010-03-25Searete LlcRemote control of substance delivery system
US8936590B2 (en)2005-11-092015-01-20The Invention Science Fund I, LlcAcoustically controlled reaction device
US9474712B2 (en)2005-11-092016-10-25Gearbox, LlcIn situ reaction device
US8906000B2 (en)2005-11-092014-12-09The Invention Science Fund I, LlcInjectable controlled release fluid delivery system
US8882747B2 (en)2005-11-092014-11-11The Invention Science Fund I, LlcSubstance delivery system
US20070149954A1 (en)*2005-11-092007-06-28Searete Llc., A Limited Liability Corporation Of The State Of DelawareAcoustically controlled substance delivery device
US9028467B2 (en)2005-11-092015-05-12The Invention Science Fund I, LlcOsmotic pump with remotely controlled osmotic pressure generation
GB2446100B (en)*2005-11-092011-11-02Searete LlcRemote controlled in vivo reaction method
US9067047B2 (en)2005-11-092015-06-30The Invention Science Fund I, LlcInjectable controlled release fluid delivery system
US8617141B2 (en)2005-11-092013-12-31The Invention Science Fund I, LlcRemote controlled in situ reaction device
US8529551B2 (en)2005-11-092013-09-10The Invention Science Fund I, LlcAcoustically controlled substance delivery device
US8568388B2 (en)2005-11-092013-10-29The Invention Science Fund I, LlcRemote controlled in situ reaction device
US8585684B2 (en)2005-11-092013-11-19The Invention Science Fund I, LlcReaction device controlled by magnetic control signal
US8998886B2 (en)2005-12-132015-04-07The Invention Science Fund I, LlcRemote control of osmotic pump device
US8273075B2 (en)2005-12-132012-09-25The Invention Science Fund I, LlcOsmotic pump with remotely controlled osmotic flow rate
US8192390B2 (en)2005-12-132012-06-05The Invention Science Fund I, LlcMethod and system for control of osmotic pump device
US8109923B2 (en)2005-12-132012-02-07The Invention Science Fund I, LlcOsmotic pump with remotely controlled osmotic pressure generation
US20100030185A1 (en)*2006-01-182010-02-04Searete LlcRemote controller for substance delivery system
US8273071B2 (en)2006-01-182012-09-25The Invention Science Fund I, LlcRemote controller for substance delivery system
US20090005727A1 (en)*2006-03-092009-01-01Searete LlcAcoustically controlled substance delivery device
US8367003B2 (en)2006-03-092013-02-05The Invention Science Fund I, LlcAcoustically controlled reaction device
US20080140057A1 (en)*2006-03-092008-06-12Searete Llc, A Limited Liability Corporation Of State Of The DelawareInjectable controlled release fluid delivery system
US20090162249A1 (en)*2006-03-092009-06-25Searete LlcAcoustically controlled reaction device
US8349261B2 (en)2006-03-092013-01-08The Invention Science Fund, I, LLCAcoustically controlled reaction device
US8083710B2 (en)2006-03-092011-12-27The Invention Science Fund I, LlcAcoustically controlled substance delivery device
US9056164B2 (en)*2007-01-012015-06-16Bayer Medical Care Inc.Radiopharmaceutical administration methods, fluid delivery systems and components thereof
US9913941B2 (en)2007-01-012018-03-13Bayer Healthcare LlcRadiopharmaceutical administration methods, fluid delivery systems and components thereof
US20080177126A1 (en)*2007-01-012008-07-24Tate Leon JRadiopharmaceutical administration methods, fluid delivery systems and components thereof
US9108047B2 (en)2010-06-042015-08-18Bayer Medical Care Inc.System and method for planning and monitoring multi-dose radiopharmaceutical usage on radiopharmaceutical injectors
US9463335B2 (en)2010-06-042016-10-11Bayer Healthcare LlcSystem and method for planning and monitoring multi-dose radiopharmaceutical usage on radiopharmaceutical injectors
US20120203264A1 (en)*2011-01-212012-08-09Endologix, Inc.Graft Systems Having Semi-Permeable Filling Structures and Methods for Their Use
US8801768B2 (en)*2011-01-212014-08-12Endologix, Inc.Graft systems having semi-permeable filling structures and methods for their use
WO2013064745A1 (en)*2011-11-012013-05-10Bayer OyOsmotically active vaginal delivery system
CN103974742A (en)*2011-11-012014-08-06拜尔公司Osmotically active vaginal delivery system
US20140309598A1 (en)*2011-11-012014-10-16Bayer OyOsmotically active vaginal delivery system
EA026830B1 (en)*2011-11-012017-05-31Байер ОйOsmotically active vaginal delivery system
AU2012330960B2 (en)*2011-11-012017-06-29Bayer OyOsmotically active vaginal delivery system
TWI615155B (en)*2011-11-012018-02-21拜耳股份有限公司Osmotically active vaginal delivery system
US9296757B2 (en)2012-05-212016-03-29Bayer Pharma AktiengesellschaftSubstituted benzothienopyrimidines
US9382255B2 (en)2012-09-202016-07-05Bayer Pharma AktiengesellschaftSubstituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors

Also Published As

Publication numberPublication date
JPS4894575A (en)1973-12-05

Similar Documents

PublicationPublication DateTitle
US3760806A (en)Helical osmotic dispenser with non-planar membrane
US3760805A (en)Osmotic dispenser with collapsible supply container
US3732865A (en)Osmotic dispenser
US3995631A (en)Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3760804A (en)Improved osmotic dispenser employing magnesium sulphate and magnesium chloride
US4034756A (en)Osmotically driven fluid dispenser
US3995632A (en)Osmotic dispenser
US3929132A (en)Osmotic dispenser
US3760984A (en)Osmotically powered agent dispensing device with filling means
US4439194A (en)Water and drug delivery system for suppository use
US3840009A (en)Self-powered vapor pressure delivery device
EP0266929B1 (en)Stressed polymeric device for controlled release of a substance to an ambient environment
US5017381A (en)Multi-unit pulsatile delivery system
US5429822A (en)Biodegradable bursting release system
US4777049A (en)Constant release system with pulsed release
US4851229A (en)Composition comprising a therapeutic agent and a modulating agent
AU595033B2 (en)Pulsatile drug delivery system
KR0183058B1 (en)Osmotic device for delayed delivery of drugs
JP2659932B2 (en) Transdermal and transmucosal drug applicators
EP0153070B1 (en)Laminate device for controlled and prolonged release of substances to an ambient environment
US6569152B2 (en)Sustained release delivery systems for solutes
US4751071A (en)Composition comprising salbutamol
JPS6210205B2 (en)
DE2247949A1 (en) DEVICE FOR ADMINISTRATION OF MEDICINAL PRODUCTS
DE2201533A1 (en) Osmotic device for the application of active agents

[8]ページ先頭

©2009-2025 Movatter.jp